Safety and efficacy of direct-acting antiviral drugs in the treatment of chronic hepatitis C virus infection in patients with thalassemia: a prospective study

Egyptian Liver Journal

Table 2 Laboratory parameters before and after treatment with DAAs

Parameter	Before	After	Statistic	P value
ALT(IU/ml)	57.29 ± 35.07	42.4545 ± 18.56	3.569	0.0005
S. bilirubin ( mg/dL)	3.17 ± 1.08	2.51 ± 1.06	4.800	0.0005
Hemoglobin (g/dL)	8.5 ± 1.34	8.64 ± 1.38	− 0.513	0.613
Platelets count (× 10⁹/L)	513.18 ± 160.47	460.14 ± 186.81	1.764	0.092
WBCs (×10⁹/L)	27.30 (18.27–51)	20.50 (12.15–49)	− 1.072	0.284

Data presented as mean ± SD except WBCs presented as median (IQR). For WBCs, data were not normally distributed (Shapiro test, p < 0.05) with the presence of significant outliers. Accordingly, Wilcoxon test was conducted. Paired samples t test was used for other parameters as the data were normally distributed